Phase II study of combination chemotherapy using paclitaxel, carboplatin, and bevacizumab in patients with advanced or recurrent cervical cancer.

Phase II study of combination chemotherapy using paclitaxel, carboplatin, and bevacizumab in patients with advanced or recurrent cervical cancer. - CC-Bev

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024137

Enrollment

Registered

2016-09-23

Start date

2016-07-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical cancer

Interventions

Paclitaxel 175mg/m2 Carboplatin AUC =6 Bevacizumab 15mg/kg Q 3 weeks

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Histologically proven cervical cancer. 2. FIGO stage IVb or recurrent cervical cancer. Previous one or two regimens of chemotherapy is permitted. 3. Patient with assessable tumor. 4. ECOG PS: 0 to 2.

Exclusion criteria

Exclusion criteria: 1. Previous paclitaxel or carboplatin administration within 6 months of registration. 2. Any active concomitant malignancy. 3. Severe comorbidity.

Design outcomes

Primary

Measure	Time frame
Objective response rate	—

Secondary

Measure	Time frame
Overall survival, Progression free survival, Toxicity	—

Countries

Japan

Contacts

Public ContactShoji Nagao

Hyogo Cancer Center Gynecologic Oncology

nagao@hp.pref.hyogo.jp078-929-1151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026